FMP

FMP

Enter

BAX - Baxter Internat...

photo-url-https://images.financialmodelingprep.com/symbol/BAX.png

Baxter International Inc.

BAX

NYSE

Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; intravenous therapies, infusion pumps, administration sets, and drug reconstitution devices; remixed and oncology drug platforms, inhaled anesthesia and critical care products and pharmacy compounding services; parenteral nutrition therapies and related products; biological products and medical devices used in surgical procedures for hemostasis, tissue sealing and adhesion prevention; and continuous renal replacement therapies and other organ support therapies focused in the intensive care unit. It also provides connected care solutions, including devices, software, communications, and integration technologies; integrated patient monitoring and diagnostic technologies to help diagnose, treat, and manage a various illness and diseases, including respiratory therapy, cardiology, vision screening, and physical assessment; surgical video technologies, tables, lights, pendants, precision positioning devices and other accessories. In addition, the company offers contracted services to various pharmaceutical and biopharmaceutical companies. Its products are used in hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices, and patients at home under physician supervision. The company sells its products through direct sales force, as well as through independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers in approximately 100 countries. It has an agreement with Celerity Pharmaceutical, LLC to develop acute care generic injectable premix and oncolytic molecules. Baxter International Inc. was incorporated in 1931 and is headquartered in Deerfield, Illinois.

30.9 USD

-0.3 (-0.971%)

Historical Prices

From:

To:

30.8530.93131.131.231.331.431.4609:30 AM09:50 AM10:10 AM10:30 AM10:50 AM11:10 AM11:30 AM11:50 AM12:10 PM12:30 PM12:50 PM01:10 PM01:30 PM01:50 PM02:10 PM02:30 PM02:50 PM03:10 PM03:30 PM03:50 PM

About

ceo

Mr. David Brent Shafer

sector

Healthcare

industry

Medical - Instruments & Supplies

exchange

NYSE

Description

Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; intravenous therapies, infusion pumps, administration sets, and drug reconstitution devices; remixed and oncology drug platforms, inhaled anesthesia and critical care products and pharmacy compounding services; parenteral nutrition therapies and related products; biological products and medical devices used in surgical procedures for hemostasis, tissue sealing and adhesion prevention; and continuous renal replacement therapies and other organ support therapies focused i...

CIK

0000010456

ISIN

US0718131099

CUSIP

071813109

Address

One Baxter Parkway

Phone

224 948 2000

Country

US

Employee

38,000

IPO Date

Oct 27, 1981

Financial Statement

-1B01B2B3B4B2024 Q12024 Q22024 Q32024 Q42025 Q1RevenueNet Income

Earnings

00.20.40.60.812023 Q22023 Q32023 Q42024 Q12024 Q22024 Q32024 Q42025 Q1EPS Consensus

BAX Financial Summary

CIK

0000010456

Exchange

NYSE

Industry

Medical - Instrument...

Sector

Healthcare

CUSIP

071813109

ISIN

US0718131099

Country

US

Price

30.9

Beta

0.63

Volume Avg.

5.03M

Market Cap

15.86B

Shares

-

52-Week

26.25-40.49

DCF

22.09

ROE

-

ROA

-

Operating Margin

-

Debt/Equity

-

P/E

-59.42

P/B

-

Website

https://www.baxter.com

Upgrades and Downgrades

We are unable to load the data!

fmp-logo

Latest BAX News

Stuart Mooney

May 1, 2025

Baxter International Inc. (NYSE:BAX) Surpasses Wall Street E...

Baxter International Inc. (NYSE:BAX) is a prominent player in the global medtech industry, known for its innovative medical devices and solutions. The company specializes in products like intravenous (IV) solutions and patient-monitoring systems, which have been in high demand. Baxter's strong market presence is reflected in its recent financial performance, where it exceeded Wall Street expectations. On May 1, 2025, Baxter reported earnings per share (EPS) of $0.623, surpassing the estimated $...

Davit Kirakosyan

Feb 20, 2025

Baxter Jumps 8% on Q4 Earnings Beat, Strong 2025 Outlook

Baxter International (NYSE:BAX) surged over 8% intra-day today after delivering better-than-expected fourth-quarter results, driven by strong sales in its Pharmaceuticals and Medical Products & Therapies divisions. For Q4, the medical technology company posted adjusted earnings per share of $0.58, exceeding the $0.52 consensus estimate. Revenue reached $2.75 billion, beating forecasts of $2.67 billion and marking a 1% year-over-year increase on a reported basis and 2% growth at constant currency...

Andrew Wynn

Feb 20, 2025

Baxter International Inc. (NYSE:BAX) Quarterly Earnings Prev...

Baxter International Inc. (NYSE:BAX) is a global healthcare company that provides a broad portfolio of essential medical products, including infusion therapies, pharmaceuticals, and patient support systems. The company is set to release its quarterly earnings on February 20, 2025. Analysts expect an earnings per share (EPS) of $0.81 and revenue of approximately $2.67 billion. Baxter has a history of surpassing earnings expectations, with an average surprise of 3.62% over the past four quarters....

Forbes

Aug 19, 2024

Baxter To Sell Its Kidney Care Unit To Carlyle For $3.8 Bill...

On August 13, 2024, Baxter International Inc. (NYSE: BAX, $36.12, Market Capitalization: $18.4 billion), a global medtech leader, and funds managed by global investment firm Carlyle (NASDAQ: CG) announced that they have signed a definitive agreement under which Carlyle will acquire Baxter's Kidney Care segment, to be named Vantive, for $3.8 billion (For details refer to spinoffresearch.com). Under the terms of the definitive agreement, subject to certain closing adjustments, Baxter will receive ...

Seeking Alpha

Aug 17, 2024

10 Great Dividend Stocks For The Next 10 Years

The focus of this article is to provide a select list of 10 dividend stocks that, in our view, are currently undervalued and should provide an average of 4.5% plus yield for the foreseeable future. We use a simple and easy-to-implement filtering method to narrow down our list to probable candidates. In our view, these dividend stocks will provide sustainable yields with decent dividend growth that will likely meet and exceed the rate of inflation.

Zacks Investment Research

Aug 14, 2024

Baxter's (BAX) Vantive Divestiture to Aid Its Operational Sa...

Baxter (BAX) announces the divestiture of its Kidney Care segment, Vantive, to a global investment firm Carlyle.

Zacks Investment Research

Aug 14, 2024

Why Baxter International (BAX) is a Top Value Stock for the ...

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Investopedia

Aug 13, 2024

Baxter Stock Falls After it Unloads Kidney Care Division in ...

Shares of Baxter International (BAX) fell Tuesday after the company said it would sell its kidney treatment division to The Carlyle Group (CG) for $3.8 billion in cash.

FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedin
2017-2025 © Financial Modeling Prep